| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/26/2002 | CA2078875C High level expression of basic fibroblast growth factor having a homogeneous n-terminus |
| 02/26/2002 | CA2063550C Azomethines agonist compounds of the histamine h3 receptor for therapeutic use, pharmaceutical compositions acting as agonists of said receptor and method of preparation |
| 02/21/2002 | WO2002014536A2 Odulating multiple lineage kinase proteins |
| 02/21/2002 | WO2002014513A1 Use of polypeptide |
| 02/21/2002 | WO2002014511A2 Regulation of human p2y1-like g protein-coupled receptor |
| 02/21/2002 | WO2002014467A2 Cng2b: a putative human cyclic nucleotide-gated ion channel |
| 02/21/2002 | WO2002014369A2 Human kininogen d5 domain polypeptides and their use |
| 02/21/2002 | WO2002014357A2 Use of gadd34 or pcna polypeptides in the treatment of cerebral ischaemic damage |
| 02/21/2002 | WO2002014356A2 Therapeutic use of a recombinant erythropoietin having high activity and reduced side effects |
| 02/21/2002 | WO2002014355A2 Novel mitogen activated kinase |
| 02/21/2002 | WO2002014351A2 α7 NICOTINIC RECEPTOR PEPTIDES AS LIGANDS FOR β AMYLOID P EPTIDES |
| 02/21/2002 | WO2002014319A2 Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| 02/21/2002 | WO2002014316A1 Process for the preparation of imidazopyridines |
| 02/21/2002 | WO2002014313A2 Novel beta-amyloid inhibitors, method for producing the same and the use thereof as medicaments |
| 02/21/2002 | WO2002014311A2 Urea compounds and methods of uses |
| 02/21/2002 | WO2002014310A1 2-[5-AMINO-6-OXO-2-PHENYL-1,6-DIHYDRO-1-PYRIMIDYL]-N-[1-(2-[5-t-BUTYL-1,3,4-OXADIAZOLYL]CARBONYL)-2-(R,S)-METHYLPROPYL]ACETAMIDE HYDROCHLORIDE |
| 02/21/2002 | WO2002014306A1 Process for the preparation of imidazopyridines |
| 02/21/2002 | WO2002014291A1 PPARδ ACTIVATORS |
| 02/21/2002 | WO2002014285A1 Substituted imidazoles as tafia inhibitors |
| 02/21/2002 | WO2002014282A1 2-aminopyridine compounds and use thereof as drugs |
| 02/21/2002 | WO2002014281A1 Pyridine derivatives as inhibitors of p38 |
| 02/21/2002 | WO2002014279A1 New aporphine esters and their use in therapy |
| 02/21/2002 | WO2002014273A1 Indoline derivatives as 5ht2c antagonists |
| 02/21/2002 | WO2002014272A1 (thio)urea derivatives, process for their production and medicines containing the derivatives |
| 02/21/2002 | WO2002014269A2 2,4-substituted pyridine derivatives |
| 02/21/2002 | WO2002014265A1 Novel 3-substituted urea derivatives and medicinal use thereof |
| 02/21/2002 | WO2002014262A1 2,3-diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage |
| 02/21/2002 | WO2002013870A2 Formulation for administering therapeutic lipophilic molecules |
| 02/21/2002 | WO2002013862A2 Method and composition for altering a b cell mediated pathology |
| 02/21/2002 | WO2002013861A2 Method and composition for altering a t cell mediated pathology |
| 02/21/2002 | WO2002013841A1 Use of extracts from ginkgo biloba leaves for inducing dreams |
| 02/21/2002 | WO2002013828A1 A retroviral immunotherapy |
| 02/21/2002 | WO2002013827A1 Process for the preparation of dinapsoline |
| 02/21/2002 | WO2002013821A1 Novel alicyclic imidazoles as h3 agents |
| 02/21/2002 | WO2002013816A1 Pharmaceutical composition |
| 02/21/2002 | WO2002013810A1 Water-soluble prodrugs of propofol for treatment of migraine |
| 02/21/2002 | WO2002013807A2 Compounds for the treatment of addictive disorders |
| 02/21/2002 | WO2002013805A2 Method of treating neurodegenerative disorders of the retina and optic nerve head |
| 02/21/2002 | WO2002013766A2 Valproic acid derivatives for the treatment of pain |
| 02/21/2002 | WO2002013758A2 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 02/21/2002 | WO2001090063A3 Prodrug of an ice inhibitor |
| 02/21/2002 | WO2001085256A3 Critical illness neuropathy |
| 02/21/2002 | WO2001080837A3 Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication |
| 02/21/2002 | WO2001080619A3 Pharmaceutical composition containing citalopram |
| 02/21/2002 | WO2001079443A3 Albumin fusion proteins |
| 02/21/2002 | WO2001077149A3 Regulation of human cyslt2-like gpcr protein |
| 02/21/2002 | WO2001072977A3 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 02/21/2002 | WO2001072960A3 Il-8 receptor antagonists |
| 02/21/2002 | WO2001072291A3 Treatment of movement disorders with metabotropic glutamate receptor antagonist |
| 02/21/2002 | WO2001070807A3 G-protein associated molecules |
| 02/21/2002 | WO2001068609B1 1,2,3,4-tetrahydroisoquinoline derivatives |
| 02/21/2002 | WO2001068065A3 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease |
| 02/21/2002 | WO2001066747A8 Proteins named fctrx and nucleic acids encoding same |
| 02/21/2002 | WO2001066089A3 Pharmaceutical compositions comprising cannabis |
| 02/21/2002 | WO2001064240A3 Methods for promoting production of myelin by schwann cells |
| 02/21/2002 | WO2001062901A3 Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof |
| 02/21/2002 | WO2001058409A3 Method of reducing aluminum levels in the central nervous system |
| 02/21/2002 | WO2001049703A3 Substituted sapogenins and their use |
| 02/21/2002 | WO2001045671A3 Suspension comprising oxcarbazepine |
| 02/21/2002 | WO2001044205A3 Phenanthryl piperazinyl dicarboxylic acids as selective nmda receptor modulating agents |
| 02/21/2002 | WO2001043775A3 Hydroxide-releasing agents as skin permeation enhancers |
| 02/21/2002 | WO2001042225A3 4-pyrimidinyl-n-acyl-l-phenylalanines |
| 02/21/2002 | WO2001032871A3 Follistatin-related protein zfsta4 |
| 02/21/2002 | WO2001031005A3 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 02/21/2002 | WO2001028516A3 Sustained-release formulations for treating cns-mediated disorders |
| 02/21/2002 | WO2001003649A3 Compositions and methods for the treatment of parkinson's disease |
| 02/21/2002 | WO2000066148A9 Novel proteins |
| 02/21/2002 | US20020022816 Device |
| 02/21/2002 | US20020022729 Pyridylfuran and pyridylthiophene compounds |
| 02/21/2002 | US20020022667 For inducing or maintaining anesthesia or sedation in a patient |
| 02/21/2002 | US20020022663 For producing analgesia in a warm blooded animal |
| 02/21/2002 | US20020022654 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 02/21/2002 | US20020022648 Novel 2H-tetrazole-amide compounds with therapeutic activity as metabotropic glutamate receptor agonists |
| 02/21/2002 | US20020022645 Administering benzofuran derivative for therapy of disease state that is capable of being modulated by inhibition of phosphodiesterase IV or Tumour Necrosis Factor |
| 02/21/2002 | US20020022643 1,1- and 1,2-disubstituted cyclopropane compounds |
| 02/21/2002 | US20020022642 As nitric oxide synthase (NOS) inhibitors, used in therapy and prophylaxis of central nervous system disorders, inflammatory disorders, septic shock and other disorders |
| 02/21/2002 | US20020022640 Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
| 02/21/2002 | US20020022637 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| 02/21/2002 | US20020022635 For therapy of cancer; inflammation; an autoimmune, infectious or ocular disease; or age-related macular degeneration |
| 02/21/2002 | US20020022630 1-phenyl-4-(1-[2-aryl]cyclopropyl) methylpiperazines: dopamine receptor ligands |
| 02/21/2002 | US20020022628 Useful as metalloproteinase inhibitor; piperazino-sulfonamide or piperidino-sulfonamide compound |
| 02/21/2002 | US20020022625 Betamimetics having a long-lasting activity, processes for preparing them, and their use as medicaments |
| 02/21/2002 | US20020022623 A substituted hydroxyethylene compound useful for treating Alzheimer's disease, mild cognitive impairment, Down's syndrome, herediatary cerebral hemmorrhage with amyloidosis, degenerative dementia |
| 02/21/2002 | US20020022622 Administering effective amount of oxalzole, thiazole or imidazole derivatives to cure diseases associated with protein aging |
| 02/21/2002 | US20020022620 Reverse-turn mimetics and methods relating thereto |
| 02/21/2002 | US20020022619 Administering to the mammal suffering from anxiety, depression and other disorders related to excessive corticotropin releasing factor an effective amount of tricyclic pyridine or pyrimidine derivatives |
| 02/21/2002 | US20020022616 Azepino[4,5-b]pyrano[3,2-e]indoles |
| 02/21/2002 | US20020022236 Accurately measuring albumin in urine sample; obtain urine, detect presence of adjusted and wildtype albumin in sample |
| 02/21/2002 | US20020022218 Methods for the identification of compounds useful for the treatment of disease states medicated by prostaglandin D2 |
| 02/21/2002 | US20020020784 Flexible kite |
| 02/21/2002 | DE10039199A1 Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen Combination preparations of ERß a selective estrogen and a SERM or antiestrogen |
| 02/21/2002 | DE10038639A1 New and known N-aryl 2-hydroxy-omega-arylalkanamide derivatives, useful e.g. for treating inflammatory diseases such as rheumatism |
| 02/21/2002 | CA2804958A1 Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| 02/21/2002 | CA2685447A1 Pharmaceutical composition |
| 02/21/2002 | CA2431954A1 A retroviral immunotherapy |
| 02/21/2002 | CA2419985A1 Modulating multiple lineage kinase proteins |
| 02/21/2002 | CA2419790A1 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 02/21/2002 | CA2419545A1 .alpha.7 nicotinic receptor peptides as ligands for .beta. amyloid peptides |
| 02/21/2002 | CA2419073A1 Novel alicyclic imidazoles as h3 agents |
| 02/21/2002 | CA2419047A1 Water-soluble prodrugs of propofol for treatment of migraine |